Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927837 | 1.00 | ALDH1A1 (0.72) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL26761468 | 0.91 | ALDH1A1 (0.85) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL31432757 | 0.85 | ALDH1A1 (0.76) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL14001912 | 0.85 | KMT2A (0.57) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL19531788 | 0.85 | KMT2A (0.62) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL4021293 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL5175917 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL4021288 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL15431334 | 0.83 | ALDH1A1 (0.72) | ALDH1A1LMNACYP2D6CYP2C19KMT2A | |
| SCHEMBL5331527 | 0.83 | LMNA (1.00) | ALDH1A1LMNACYP2D6CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8586600-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8242271-B2 | Heterocyclic compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2152079-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008151183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ALDH1A1 261/4885LMNA 1530/4885CYP2D6 16/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ALDH1A1 261/4885LMNA 1530/4885CYP2D6 16/4885 |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ALDH1A1 261/4885LMNA 1530/4885CYP2D6 16/4885 |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ALDH1A1 261/4885LMNA 1530/4885CYP2D6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.